Clinical Trials
22 trialsNCT06597734 2026-05-20
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04953312 2026-03-12
CALPRO
Assistance Publique - Hôpitaux de Paris
Phase NA Withdrawn
NCT05895201 2024-04-29
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
Phase 1/2 Withdrawn
NCT06085638 2024-03-07
Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT05456269 2023-10-03
BISECT
Racura Oncology Ltd
Phase 1 Withdrawn
NCT00816413 2023-08-14
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
Phase 1/2 Withdrawn
NCT05246384 2022-10-31
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Rhizen Pharmaceuticals SA
Phase 1/2 Withdrawn
NCT04264806 2022-05-20
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
Janssen Research & Development, LLC
Phase 2 Withdrawn
NCT00900120 2021-09-21
Collecting and Storing Blood Samples From Patients With Cancer
Rutgers, The State University of New Jersey
Withdrawn
NCT04217720 2021-08-12
SNS-301 Monotherapy in High Risk MDS and CMML
Sensei Biotherapeutics, Inc.
Phase 2 Withdrawn
NCT03602898 2021-06-30
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT03807063 2020-08-14
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT00004114 2020-07-31
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT00085449 2019-11-27
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Withdrawn
NCT02564536 2017-05-08
Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
Washington University School of Medicine
Phase 1 Withdrawn
NCT00770419 2015-05-29
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
Rutgers, The State University of New Jersey
Withdrawn
NCT00898612 2014-03-10
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
Mayo Clinic
Withdrawn
NCT00499668 2013-04-02
Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
Vanderbilt-Ingram Cancer Center
Phase NA Withdrawn
NCT01101412 2013-02-15
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00301912 2012-10-02
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT01558778 2012-07-09
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Phase NA Withdrawn
NCT00378781 2012-02-24
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
M.D. Anderson Cancer Center
Phase NA Withdrawn